The neutralization of CSF1/CSF1R signaling by multiple approaches such as CSF1R-blocking antibodies and small molecules tyrosine kinase inhibitors has been demonstrated to efficiently deplete TAMs in several pre-clinical models such as fibrosarcoma, mesothelioma, colorectal, lung, prostate and pancreatic cancer [103]. The gene discussed is CSF1R; the disease is pancreatic neoplasm.